ストックスクリーナーアプリを入手
2.68
2.55%
-0.07
アフターアワーズ：
2.68
前日終値:
$2.75
開ける：
$2.78
24時間の取引高:
892.59K
Relative Volume:
1.17
時価総額：
$92.96M
収益：
-
当期純損益:
$-32.94M
株価収益率:
-2.4144
EPS:
-1.11
ネットキャッシュフロー:
$-24.95M
1週間 パフォーマンス:
+15.52%
1か月 パフォーマンス:
-14.65%
6か月 パフォーマンス:
-13.27%
1年 パフォーマンス:
-43.70%
1日の値動き範囲:
$2.67
$2.82
1週間の範囲:
$2.46
$2.85
52週間の値動き範囲:
$1.84
$5.31
Achieve Life Sciences Inc Stock (ACHV) Company Profile
名前
Achieve Life Sciences Inc
セクター
電話
425-686-1500
住所
22722 29TH DR. SE, SEATTLE, BC
ACHV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACHV
Achieve Life Sciences Inc
|
2.68 | 115.27M | 0 | -32.94M | -24.95M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2024-09-27 | 開始されました | Raymond James | Strong Buy |
| 2023-05-10 | 繰り返されました | Maxim Group | Buy |
| 2021-06-23 | 開始されました | Oppenheimer | Outperform |
Achieve Life Sciences Inc (ACHV) 最新ニュース
Is Achieve Life Sciences Inc. a good long term investmentFree Stock Market Forecast Reports - Jammu Links News
Will Achieve Life Sciences Inc. stock split in the near futureFree Real-Time Market Predictions - Newser
What makes Achieve Life Sciences Inc. stock price move sharplyFree Discussion Group - Newser
Why Achieve Life Sciences Inc. stock attracts strong analyst attentionShort Squeeze Radar - Newser
How Achieve Life Sciences Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Company’s Banking Shares: Up -49.72% from 52-Week Low, But Can the Momentum Hold? - investchronicle.com
Omnicom, Achieve Life Sciences Partner for AI-Driven Launch of New Nicotine Dependence Treatment - MSN
Achieve Life Sciences: The AI-Powered Push to Redefine Smoking Cessation - AInvest
Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation - Seeking Alpha
Should You Hold Achieve Life Sciences (ACHV)? - Insider Monkey
ACHV: Achieve’s Busy Day - Yahoo Finance
Achieve Life Sciences (ACHV) Receives a Buy from Raymond James - The Globe and Mail
Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering - MSN
CSW INDUSTRIALS EVP, CFO Sell Shares at $284.18/Share on 2025-07-01. - AInvest
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities | ACHV Stock News - GuruFocus
Achieve Life Sciences, Inc.(NasdaqCM: ACHV) dropped from Russell 3000 Index - MarketScreener
Achieve Life Sciences, Inc.(NasdaqCM: ACHV) dropped from Russell 3000 Growth Index - MarketScreener
Achieve Life Sciences: Riding the Nicotine Cessation Wave, But Can It Overcome Regulatory Hurdles? - AInvest
Bothell biotech firm plans $45 million public offering to advance smoking cessation drug - The Business Journals
Tech And Biotech Stocks Take A Dive Following Surprising Announcements - Finimize
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Achieve Life Sciences (ACHV) Submits FDA Application for Smoking Cessation Drug | ACHV Stock News - GuruFocus
ACHV Gains Attention with Strategic Financial Moves | ACHV Stock News - GuruFocus
Achieve Life Sciences (ACHV) Launches $45 Million Stock Offering - GuruFocus
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation - The Manila Times
Achieve Life Sciences Announces Pricing of $45.0 Million Underwr - GuruFocus
Achieve Life Sciences announces proposed public offering; shares down nearly 13% - MSN
Achieve Life Sciences announces public offering to fund cytisinicline By Investing.com - Investing.com Canada
Achieve Life Sciences Announces Submission of NDA to FDA - GlobeNewswire
Breakthrough Smoking Cessation Drug Could Help 29M Americans: FDA Review Begins - Stock Titan
Achieve adds vapers to smokers in targeting multi-billion dollar market - The Pharma Letter
Bank of America Corp DE Purchases 9,760 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
Institutional investors may adopt severe steps after Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) latest 15% drop adds to a year losses - simplywall.st
Owning 46% shares,institutional owners seem interested in Achieve Life Sciences, Inc. (NASDAQ:ACHV), - Yahoo
Squarepoint Ops LLC Buys Shares of 17,519 Achieve Life Sciences, Inc. (NASDAQ:ACHV) - Defense World
achieve life sciences holds annual meeting with key votes By Investing.com - Investing.com India
Achieve Life Sciences Elects Board at Annual Meeting - TipRanks
achieve life sciences holds annual meeting with key votes - Investing.com
Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above 200 Day Moving Average – What’s Next? - Defense World
Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk (ACHV) - Seeking Alpha
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Late-Stage Smoking Cessation Drug Developer Achieve Life Sciences Sets Key Jefferies Conference Presentation - Stock Titan
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Purchased by Northern Trust Corp - Defense World
Shay Capital LLC Sells 425,000 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat
ACHV: New Insights from ORCA-3 Study to Be Shared at 2025 Conference | ACHV Stock News - GuruFocus
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake | ACHV Stock News - GuruFocus
Achieve Life Sciences to Present Phase 3 Study Findings on Cytisinicline for Smoking Cessation at 2025 ATS Conference - Nasdaq
Achieve Life Sciences Inc (ACHV) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.34%
大文字化:
|
ボリューム (24 時間):